AI
ZURA icon

Allostery Investments’s Zura Bio ZURA Stock Holding History

Allostery Investments’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,329,384
Closed -$3M – 44
2025
Q1 		$3M Buy
2,329,384
+814,258
+54% +$1.28M 4.33% 9
2024
Q4 		$3.79M Buy
+1,515,126
New +$5.4M 3.96% 9

Other funds holding ZURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Allostery Investments's ZURA Position: Q2 2025 in Review

Allostery Investments sold out of Zura Bio (ZURA) in Q2 2025, closing a stake of 2,329,384 shares — an estimated $3M sold.

Allostery Investments first reported a position in ZURA in Q4 2024 and held it in 2 quarters. The position peaked at $3.79M in Q4 2024. 65 funds tracked by Wall St. Rank hold ZURA as of Q2 2025.

  • Allostery Investments reported no remaining Zura Bio position as of Q2 2025 after selling out during the quarter.
  • Allostery Investments sold 2,329,384 Zura Bio shares in Q2 2025, an estimated $3M.
  • Allostery Investments first reported a position in Zura Bio in Q4 2024 and held it in 2 quarters.
  • Allostery Investments's Zura Bio position peaked at $3.79M in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Zura Bio as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.